Information Journal Paper
APA:
Copy. (2018). Recombinant Human Soluble Thrombomodulin as an Anticoagulation Therapy Improves Recurrent Miscarriage and Fetal Growth Restriction due to Placental Insufficiency– the Leading Cause of Preeclampsia. Placenta, 65(-), 1-6. SID. https://sid.ir/paper/744231/en
Vancouver:
Copy. Recombinant Human Soluble Thrombomodulin as an Anticoagulation Therapy Improves Recurrent Miscarriage and Fetal Growth Restriction due to Placental Insufficiency– the Leading Cause of Preeclampsia. Placenta[Internet]. 2018;65(-):1-6. Available from: https://sid.ir/paper/744231/en
IEEE:
Copy, “Recombinant Human Soluble Thrombomodulin as an Anticoagulation Therapy Improves Recurrent Miscarriage and Fetal Growth Restriction due to Placental Insufficiency– the Leading Cause of Preeclampsia,” Placenta, vol. 65, no. -, pp. 1–6, 2018, [Online]. Available: https://sid.ir/paper/744231/en